Pancreatic Cancer Research

ResearcherSanofi (France)Active in the last 2 years

Hanno B. Riess

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5111483106. Sources: OpenAlex.

Their work

Papers
45 (first author 6, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 6 papers · 2014: 7 papers · 2015: 7 papers · 2016: 3 papers · 2017: 5 papers · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 45

  1. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Co-author DOI 10.1002/2056-4538.12377↗
  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  3. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
  4. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. Co-author DOI 10.1002/ejhf.2059↗
  5. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327↗
  6. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  7. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  8. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. First author DOI 10.3389/fonc.2021.670396↗
  9. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Co-author DOI 10.1002/cam4.3269↗
  10. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  11. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… Co-author DOI 10.1097/mpa.0000000000001507↗
  12. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  13. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Last author DOI 10.1016/j.ejca.2018.06.001↗
  14. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  15. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. First author DOI 10.1007/s11523-016-0469-y↗
  16. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  17. Pancreatic cancer: moving forward, step by step. Co-author DOI 10.1016/s2468-1253(17)30055-9↗
  18. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Last author DOI 10.1200/jco.2017.72.6463↗
  19. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Co-author DOI 10.1371/journal.pone.0186341↗
  20. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  21. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. Co-author DOI 10.1097/mpa.0000000000000533↗
  22. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. Last author DOI 10.4251/wjgo.v8.i3.248↗
  23. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Co-author DOI 10.1002/jso.23951↗
  24. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… First author DOI 10.1016/j.ejca.2015.05.005↗
  25. CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Co-author DOI 10.1016/s1499-3872(15)60409-x↗
  26. [Current standards in the treatment of pancreatic cancer]. First author DOI 10.1055/s-0041-107888↗
  27. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000365↗
  28. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Last author DOI 10.1159/000441310↗
  29. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Last author DOI 10.1200/jco.2014.55.1481↗
  30. [Multimodal treatment of pancreatic cancer]. Last author DOI 10.1007/s00108-013-3316-6↗
  31. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  32. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  33. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000077↗
  34. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy. Last author DOI 10.1155/2014/452089↗
  35. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. Last author DOI 10.1186/1471-2407-14-204↗
  36. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from … First author DOI 10.1200/jco.2013.53.6995↗
  37. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Last author DOI 10.1001/jama.2013.279201↗
  38. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  39. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine… First author DOI 10.1016/j.ejca.2013.04.002↗
  40. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Last author DOI 10.1055/s-0033-1349608↗
  41. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Last author DOI 10.3389/fonc.2013.00155↗
  42. Blood group determinates incidence for pancreatic cancer in Germany. Last author DOI 10.3389/fphys.2013.00118↗
  43. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗
  44. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CO… Co-author DOI 10.1007/s00280-011-1602-3↗
  45. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase I… Co-author DOI 10.1016/j.ejca.2011.04.011↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 32 shared papers, 2011–2024 · strength 2.13
  2. Marianne Sinn · 31 shared papers, 2013–2024 · strength 2.04
  3. Helmut Oettle · 21 shared papers, 2011–2024 · strength 1.41
  4. Jana Käthe Striefler · 20 shared papers, 2012–2022 · strength 1.33
  5. Marcus Bahra · 22 shared papers, 2012–2021 · strength 1.27
  6. Jens Stieler · 17 shared papers, 2011–2022 · strength 0.81
  7. Philipp Lohneis · 9 shared papers, 2014–2021 · strength 0.61
  8. Bruno Valentin Sinn · 11 shared papers, 2012–2021 · strength 0.60
  9. Carsten Denkert · 11 shared papers, 2012–2021 · strength 0.60
  10. Fritz Klein · 6 shared papers, 2013–2018 · strength 0.35
  11. Anja Jühling · 4 shared papers, 2016–2018 · strength 0.26
  12. Timm Denecke · 4 shared papers, 2015–2018 · strength 0.24
  13. Annika Kurreck · 2 shared papers, 2021 · strength 0.24
  14. Dominik Paul Modest · 2 shared papers, 2021 · strength 0.24
  15. Andrew Eugene Hendifar · 2 shared papers, 2020–2021 · strength 0.22
  16. Amylou Constance Dueck · 2 shared papers, 2020–2021 · strength 0.22
  17. Do‐Youn Oh · 2 shared papers, 2020–2021 · strength 0.22
  18. Marc F Botteman · 2 shared papers, 2020–2021 · strength 0.22
  19. Chung‐Pin Li · 2 shared papers, 2020–2021 · strength 0.22
  20. Michele Reni · 2 shared papers, 2020–2021 · strength 0.22
  21. Margaret A. Tempero · 2 shared papers, 2020–2021 · strength 0.22
  22. Teresa Mercade Macarulla · 2 shared papers, 2020–2021 · strength 0.22
  23. Alexander Muckenhuber · 1 shared paper, 2024 · strength 0.21
  24. Jia Rao · 1 shared paper, 2024 · strength 0.21
  25. Helmut Friess · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.